PHARMACEUTICAL COMPOSITION ELICITING THROMBOLYTIC AND FIBRINOLYTIC EFFECT

FIELD: medicine, pharmacy. SUBSTANCE: composition comprises the modified plasminogen activator of urokinase type mAPUT22 with specific activity 80 000-100 000 IU/mg of enzyme as an active substance that shows the definite amino acid sequence consisting of 403 amino acids and taken in the effective t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BIBILASHVILI R.SH, GURSKIJ JA.G, DEL'VER E.P, BELOGUROV A.A, TOVAROVA I.I
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: medicine, pharmacy. SUBSTANCE: composition comprises the modified plasminogen activator of urokinase type mAPUT22 with specific activity 80 000-100 000 IU/mg of enzyme as an active substance that shows the definite amino acid sequence consisting of 403 amino acids and taken in the effective therapeutic dose and excipient also. Composition contains dextran with molecular mass 10 000-70 000 Da and sodium chloride as excipients. Composition can be used in ophthalmology. The novel composition shows the enhanced specific fibrinolytic and thrombolytic activity, it doesn't cause danger adverse effects in treatment of intraocular hemorrhages and fibrinous exudates arising in traumas and inflammatory diseases of eyes. EFFECT: enhanced effectiveness and valuable medicinal properties of composition. 5 cl